Multicenter Clinical Validation of PITX2 Methylation as a Prostate Specific Antigen Recurrence Predictor in Patients With Post-Radical Prostatectomy Prostate Cancer

Journal of Urology

Volumn 184, Issue 1, 2010, Pages 149-156

  Bañez, Lionel L ^a,c   Sun, Leon ^a   van Leenders, Geert J ^d   Wheeler, Thomas M ^e   Bangma, Chris H ^d   Freedland, Stephen J ^b,c   Ittmann, Michael M ^e   Lark, Amy L ^c   Madden, John F ^b   Hartman, Arndt ^f   Weiss, Gunter ^g   Castaños Vélez, Esmeralda ^g  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g EPIGENOMICS AG   (Germany)

Author keywords

methylation; neoplasm recurrence; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR PITX2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CLINICAL FEATURE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROARRAY ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; VALIDATION STUDY;

ADENOCARCINOMA; ADULT; AGED; DNA METHYLATION; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953123406     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.012     Document Type: Article

References (29)

1. Cancer Facts and Figures 2009 (2009), American Cancer Society, Atlanta
2. Bray F., Sankila R., Ferlay J., et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 (2002) 99
3. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
4. Shariat S.F., Karakiewicz P.I., Suardi N., et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14 (2008) 4400
5. Shariat S.F., Karam J.A., Walz J., et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14 (2008) 3785
6. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148
7. Sanchez-Cespedes M., Esteller M., Hibi K., et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res 5 (1999) 2450
8. Kollermann J., Muller M., Goessl C., et al. Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur Urol 44 (2003) 533
9. Brock M.V., Hooker C.M., Ota-Machida E., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358 (2008) 1118
10. Kioussi C., Briata P., Baek S.H., et al. Identification of a Wnt/Dvl/beta-Catenin -> Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 111 (2002) 673
11. Semina E.V., Reiter R., Leysens N.J., et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 14 (1996) 392
12. Toyota M., Kopecky K.J., Toyota M.O., et al. Methylation profiling in acute myeloid leukemia. Blood 97 (2001) 2823
13. Anglim P.P., Galler J.S., Koss M.N., et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 7 (2008) 62
14. Harbeck N., Nimmrich I., Hartmann A., et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26 (2008) 5036
15. Weiss G., Cottrell S., and Distler J. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker for biochemical recurrence in prostate cancer patients after radical prostatectomy. J Urol 181 (2009) 1678
16. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
17. Schatz P., Dietrich D., Koenig T., et al. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J Mol Diagn (2010) Epub ahead of print
18. Kattan M.W. Evaluating a new marker's predictive contribution. Clin Cancer Res 10 (2004) 822
19. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol 171 (2004) 1393
20. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157
21. Touijer K., Kuroiwa K., Vickers A., et al. Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. Eur Urol 49 (2006) 853
22. Fradet V., Lessard L., Begin L.R., et al. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10 (2004) 8460
23. Nimmrich I., Sieuwerts A.M., Meijer-van Gelder M.E., et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 111 (2008) 429
24. Lopez-Otin C., and Diamandis E.P. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 19 (1998) 365
25. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181 (2009) 956
26. Porter C.R., Capitanio U., Perrotte P., et al. Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer-specific survival in a matched case-control study. BJU Int 103 (2009) 597
27. McLeod D.G. Success and failure of single-modality treatment for early prostate cancer. Rev Urol 2 suppl. (2004) S13
28. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54 (2008) 816
29. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141